SleepNCT06267586
Effects of PeptiSleep in Healthy Males and Females With Mild to Moderate Sleep Impairment
A study testing PeptiSleep in people with Sleep, run by Nuritas Ltd at 1 site in Australia.
Trial summary
Examining the effects of PeptiSleep, a plant-based sleep aid, in healthy males and females with mild to moderate sleep impairment Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Sleep
- What is being tested?
- PeptiSleep
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteAustralia
- Study dates
- 8 Apr 2024to 1 Mar 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Males and females 18-65 years
- Generally healthy
- BMI 18.5 - 33.0.kg/m2
- Volunteers who score 0-14 on the ISI screening questionnaire (to exclude insomniacs)
- Those with an average sleep score of 89 or less as determined by the sleep tracker during the 14-day run-in period
- Must be willing to wear the sleep tracker for the duration of their enrolment
Show all 10Show fewer
- Able to provide informed consent
- Agree not to change current diet and/or exercise frequency or intensity during entire enrolment period
- Agree not to use other medicines or supplements for sleep, stress, depression, or anxiety other than the test product during enrolment period
- Agree to not participate in another clinical trial during enrolment period
Who cannot join
- Those diagnosed with a chronic sleep disorder, insomnia, restless leg syndrome, sleep apnoea or score of 15 or more on ISI questionnaire
- Those with an average sleep score of 90 or over as determined by the sleep tracker during the 14-day run-in period
- Those deemed unsuitable based on data from the sleep tracker measurements collected during the 14-day run in period i.e., those with non-wear time exceeding a 24-hour period on more than one occasion
- Those using medications which induce CYP3A4 such as phenobarbital, phenytoin, rifampicin, St. John's Wort, and glucocorticoids.
- Those using prescription or OTC medications or supplements for sleep, stress, depression or anxiety including CBD within 1 month prior to enrolment.
- Those using aromatherapy to help manage sleep, stress, depression, or anxiety within 1 month prior to enrolment.
Show all 26Show fewer
- Use of a digital device (besides the supplied sleep tracker) to help monitor or manage sleep during the study period.
- Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years
- Serious illness1 e.g., mood disorders such as depression, anxiety or bipolar disorder, neurological disorders such as MS, kidney disease, liver disease or heart conditions
- Unstable illness2 e.g., diabetes and thyroid gland dysfunction
- Diagnosed or consistent gastrointestinal issues that disrupt sleep.
- History of renal function impairment
- Volunteers with COPD or a chronic breathing disorder
- Currently taking Coumadin (Warfarin), Heparin, Dalteparin, Enoxaparin or other anticoagulation therapy including low dose aspirin
- Active smokers, nicotine use or drug (prescription or illegal substances) abuse
- Chronic past and/or current alcohol use (>14 alcoholic drinks week)
- Regularly taking stimulants (e.g., coffee, caffeine supplements, beverages containing caffeine) 5 hours before bed
- Regularly consuming more than 500mg of caffeine per day
- Those working night-shift employment who are unable to have a normal night's sleep.
- Disturbed sleeping pattern caused by external factors (e.g., young children, partner etc.)
- Pregnant or lactating women
- Allergic, sensitive, or intolerant to any of the ingredients in active or placebo formula
- Participants who are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 1 month and any other sleep clinical trial during the past 3 months.
- Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion.
- A serious illness is a condition that carries a risk of mortality, negatively impacts quality of life and daily function and/or is burdensome in symptoms and/or treatments.
- An unstable illness is any illness that is currently not being treated with a stable dose of medication or is fluctuating in severity.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Examining the Effects of PeptiSleep, a Plant-based Sleep Aid, in Healthy Males and Females With Mild to Moderate Sleep Impairment
Examining the effects of PeptiSleep, a plant-based sleep aid, in healthy males and females with mild to moderate sleep impairment
Read the detailed description
The primary aim of this is a first in human study is to evaluate safety and establish the effective dose in males and females who experience mild to moderate sleep impairment, but who are otherwise healthy. PeptiSleep will be supplemented one hour before bed as a single oral dose of either 250mg, 500mg or 1000mg/day. A placebo group will also be included who will receive 500mg of microcrystalline cellulose.
This trial incorporates a sleep tracking element to measure sleep quality and quantity via a ring which will be worn by participants for the duration of the study. The trial will be conducted over 10 weeks, which includes a 2 week run-in period to gather baseline sleep data, followed by 8 weeks of PeptiSleep supplementation and sleep tracking.
The primary endpoint will measure safety and tolerability via adverse event reporting and incidence rate ratio between placebo and PeptiSleep from baseline to the end of the study period.
Secondary endpoints investigated during the trial will include changes sleep quantity and quality, insomnia severity, daytime sleepiness, stress and anxiety, alertness, and biochemistry markers (melatonin, serotonin, CRP, TNFα, IL-6, E/LFT).
Exploratory endpoints will include various sleep metrics measured via the wearable tracker including heart rate variability, sleep efficiency, respiratory rate, blood oxygen sensing and daily readiness score.
- Conditions
- Sleep
- Being tested
- PeptiSleep, Placebo MCC micro-crystalline cellulose
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PeptiSleepDietary supplement
Plant protein hydrolysate
Placebo MCC micro-crystalline celluloseDietary supplement
Placebo MCC micro-crystalline cellulose
| Study group | Role | What they receive |
|---|---|---|
| PeptiSleep 250 mg/day | Experimental | Low dose Given as 1 capsule 1 hour before bed Receives: Dietary Supplement: PeptiSleep |
| PeptiSleep 500 mg/day | Experimental | Middle dose Given as 2 capsules 1 hour before bed Receives: Dietary Supplement: PeptiSleep |
| PeptiSleep 1000 mg/day | Experimental | High dose Given as 4 capsules 1 hour before bed Receives: Dietary Supplement: PeptiSleep |
| Microcrystalline Cellulose 500mg/day | Placebo comparator | Placebo Given as 2 capsules 1 hour before bed Receives: Dietary Supplement: Placebo MCC micro-crystalline cellulose |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety and Tolerability of a dose range of PeptiSleep via adverse event reporting
Change from baseline to the end of the study period in safety via adverse event reporting and incident rate ratio between placebo and a dose range of PeptiSleep
Measured: Day 0 to 56
Secondary outcomes (19)
Safety via electrolytes and liver function tests
Change from baseline to the end of the study period in safety including electrolytes and liver function markers via blood test
Measured: Day 0 to 56
Sleep Quality via Leeds Sleep Evaluation Questionnaire
Change from baseline to the end of the study period in Sleep Quality via Leeds Sleep Evaluation Questionnaire (LSEQ). The LSEQ comprises ten self-rating 100-mm-line analogue questions concerned with aspects of sleep and early morning behaviour. A visual analogue scale is used with two extreme states defined at the ends of the line (e. g. Tired = score of 0, Alert = score of 10). The subject responds by placing a vertical mark on the line to indicate his present self- evaluation.
The four subscales are as follows:
- The ease of getting to sleep (GTS), questions 1-3
- The perceived quality of sleep (QOS), questions 4-5
- The easy of awakening from sleep (AFS), questions 6-7
- The integrity of behaviour following wakefulness (BFW), questions, 8-10
Measured: Day 0 to 56
Insomnia severity via the Insomnia Severity Index Questionnaire
Change from baseline to the end of the study period in Insomnia Severity via Insomnia Severity Index (ISI). The questionnaire has seven questions. The seven answers are added up to get a total score.
Total score categories:
- 0-7 = No clinically significant insomnia
- 8-14 = Subthreshold insomnia
- 15-21 = Clinical insomnia (moderate severity)
- 22-28 = Clinical insomnia (severe)
Measured: Day 0 to 56
Sleep onset time via self-reported recording in a Sleep Diary
Change from baseline to the end of the study period in Sleep Onset Time via Consensus Sleep Diary (CSD)
Measured: Day 0 to 56
Sleep pattern via self-reported recording in a Sleep Diary
Change from baseline to the end of the study period in self reported Sleeping Pattern and number of Disturbance as recorded using a Consensus Sleep Diary (CSD)
Measured: Day 0 to 56
Daytime Sleepiness via the Epworth Sleepiness Scale
Change from baseline to the end of the study period in Day Time Sleepiness and Nap Count via the Epworth Sleepiness Scale (ESS). The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher the propensity for daytime sleepiness
- Scores 0-5 Lower Normal Daytime Sleepiness
- Scores 6-10 Higher Normal Daytime Sleepiness
- Scores 11-12 Mild Excessive Daytime Sleepiness
- Scores 13-15 Moderate Excessive Daytime Sleepiness
- Scores 16-24 Severe Excessive Daytime Sleepiness.
Measured: Day 0 to 56
Stress via the Perceived Stress Scale
Change from baseline to the end of the study period in Stress via a self reported questionnaire - Perceived Stress Scale (PSS). The questions in this scale ask about feelings and thoughts during the last month. The questionnaire asks the participant to indicate how often they felt or thought a certain way with 0 meaning never and 4 meaning very often.
PSS scores are calculated by:
- First, reverse your scores for questions 4, 5, 7, and 8. On these 4 questions, change the scores like this: 0 = 4, 1 = 3, 2 = 2, 3 = 1, 4 = 0.
- Add up your scores for each item to get a total.
- Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress.
- Scores ranging from 0-13 would be considered low stress.
- Scores ranging from 14-26 would be considered moderate stress.
- Scores ranging from 27-40 would be considered high perceived stress
Measured: Day 0 to 56
Stress via self reported Profile of Mood States Questionnaire
Change from baseline to the end of the study period in Stress via a self reported questionnaire called Profile of Mood States (POMS). The questionnaire contains 65 words that describe feelings which are rated from 0-4. Scores are calculated:
- Tension = Tense, Shaky, On Edge, Panicky, Relaxed, Uneasy, Restless, Nervous and Anxious
- Depression = Unhappy, Sorry for Things Done, Sad, Blue, Hopeless, Unworthy, Discouraged, Lonely, Miserable, Gloomy, Desperate, Helpless, Worthless, Terrified and Guilty
- Anger = Anger, Peeved, Grouchy, Spiteful, Annoyed, Resentful, Bitter, Ready to Fight, Rebellious, Deceived, Furious and Bad Tempered
- Fatigue = Worn Out, Listless, Fatigued, Exhausted, Sluggish, Weary and Bushed
- Confusion= Confused, Unable to Concentrate, Muddled, Bewildered, Efficient, Forgetful, and Uncertain About Things
- Vigour =Lively, Active, Energetic, Cheerful, Alert, Full of Pep, Carefree and Vigorous
Measured: Day 0 to 56
Anxiety via self-reported Beck Anxiety Inventory questionnaire
Change from baseline to the end of the study period in Anxiety via Beck Anxiety Inventory (BAI) questionnaire. The BAI consists of 21 self-reported items on a four-point scale - ''not at all'' (0) to ''severely'' (3) to assess the intensity of physical and cognitive anxiety symptoms during the past week. Scores may range from 0 to 63
- Minimal anxiety levels (0-7)
- Mild anxiety (8-15)
- Moderate anxiety (16-25)
- Severe anxiety (26-63)
Measured: Day 0 to 56
Stress via Salivary cortisol test
Change from baseline to the end of the study period in Stress via Salivary cortisol test
Measured: Day 0 to 56
Alertness via Reaction Time Test
Change from baseline to the end of the study period in Alertness via Reaction Time Test
Measured: Day 0 to 56
Circadian cycles via melatonin and serotonin via blood test
Change from baseline to the end of the study period in markers associated with circadian cycles - melatonin and serotonin via blood test
Measured: Day 0 to 56
Markers associated with inflammation via blood test
Change from baseline to the end of the study period in Inflammatory Markers such as CRP, TNF-α and IL-6 via blood test
Measured: Day 0 to 56
Sleep onset latency via wearable sleep tracker
Change from baseline to the end of the study sleep onset latency measured in minutes using a wearable sleep tracker
Measured: Day 0 to 56
Total sleep time spent in sleep phases via wearable sleep tracker
Change from baseline to the end of the study in total sleep time during phases of light, deep and REM sleep measured in minutes via a wearable sleep tracker
Measured: Day 0 to 56
Blood pressure via blood pressure machine
Change from baseline to the end of the study in blood pressure measured in mmHG
Measured: Day 0 to 56
Heart rate via blood pressure machine
Change from baseline to the end of the study in heart rate measured in beats per minute using a blood pressure machine
Measured: Day 0 to 56
Body Temperature via wearable sleep tracker
Change from baseline to the end of the study in body temperature measured in Celsius using a wearable sleep tracker
Measured: Day 0 to 56
BMI via height and weight measurements
Change from baseline to the end of the study in BMI. The BMI is calculated by dividing weight in kilograms by height in meters squared and is measured in kg/m2.
Measured: Day 0 to 56
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Feb 2024
- Study start8 Apr 2024
- Primary completion30 Dec 2024
- Study completion1 Mar 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SleepStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized, single-blind, placebo-controlled, parallel dose response study conducted over 70 days
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Nuritas Ltd
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- RDC Clinical Pty Ltd
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06267586
- Sponsor's protocol ID
- PN23.007
- Status last verified
- Mar 2025
- First submitted
- 2 Feb 2024
- Last updated
- 13 Mar 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Examining the Effects of PeptiSleep, a Plant-based Sleep Aid, in Healthy Males and Females With Mild to Moderate Sleep Impairment
- ClinicalTrials.gov ID
- NCT06267586
- Acronym / sponsor ID
- PN23.007
- Conditions
- Sleep
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Nuritas LtdIndustry (pharma, biotech, devices)
- Collaborators
- RDC Clinical Pty Ltd
- Study start
- 8 Apr 2024 (actual)
- Primary completion
- 30 Dec 2024 (actual)
- Study completion
- 1 Mar 2025 (actual)
- First posted
- 20 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Examining the effects of PeptiSleep, a plant-based sleep aid, in healthy males and females with mild to moderate sleep impairment
Detailed description
The primary aim of this is a first in human study is to evaluate safety and establish the effective dose in males and females who experience mild to moderate sleep impairment, but who are otherwise healthy. PeptiSleep will be supplemented one hour before bed as a single oral dose of either 250mg, 500mg or 1000mg/day. A placebo group will also be included who will receive 500mg of microcrystalline cellulose.
This trial incorporates a sleep tracking element to measure sleep quality and quantity via a ring which will be worn by participants for the duration of the study. The trial will be conducted over 10 weeks, which includes a 2 week run-in period to gather baseline sleep data, followed by 8 weeks of PeptiSleep supplementation and sleep tracking.
The primary endpoint will measure safety and tolerability via adverse event reporting and incidence rate ratio between placebo and PeptiSleep from baseline to the end of the study period.
Secondary endpoints investigated during the trial will include changes sleep quantity and quality, insomnia severity, daytime sleepiness, stress and anxiety, alertness, and biochemistry markers (melatonin, serotonin, CRP, TNFα, IL-6, E/LFT).
Exploratory endpoints will include various sleep metrics measured via the wearable tracker including heart rate variability, sleep efficiency, respiratory rate, blood oxygen sensing and daily readiness score.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 4
- Model description
- Randomized, single-blind, placebo-controlled, parallel dose response study conducted over 70 days
| Arm | Type | Receives |
|---|---|---|
| PeptiSleep 250 mg/day | Experimental | Dietary Supplement: PeptiSleepLow dose Given as 1 capsule 1 hour before bed |
| PeptiSleep 500 mg/day | Experimental | Dietary Supplement: PeptiSleepMiddle dose Given as 2 capsules 1 hour before bed |
| PeptiSleep 1000 mg/day | Experimental | Dietary Supplement: PeptiSleepHigh dose Given as 4 capsules 1 hour before bed |
| Microcrystalline Cellulose 500mg/day | Placebo comparator | Dietary Supplement: Placebo MCC micro-crystalline cellulosePlacebo Given as 2 capsules 1 hour before bed |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Males and females 18-65 years
- Generally healthy
- BMI 18.5 - 33.0.kg/m2
- Volunteers who score 0-14 on the ISI screening questionnaire (to exclude insomniacs)
- Those with an average sleep score of 89 or less as determined by the sleep tracker during the 14-day run-in period
Key exclusion criteria (26 listed)
- Those diagnosed with a chronic sleep disorder, insomnia, restless leg syndrome, sleep apnoea or score of 15 or more on ISI questionnaire
- Those with an average sleep score of 90 or over as determined by the sleep tracker during the 14-day run-in period
- Those deemed unsuitable based on data from the sleep tracker measurements collected during the 14-day run in period i.e., those with non-wear time exceeding a 24-hour period on more than one occasion
- Those using medications which induce CYP3A4 such as phenobarbital, phenytoin, rifampicin, St. John's Wort, and glucocorticoids.
- Those using prescription or OTC medications or supplements for sleep, stress, depression or anxiety including CBD within 1 month prior to enrolment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PeptiSleepPlant protein hydrolysate | Dietary supplement | PeptiSleep 1000 mg/day, PeptiSleep 250 mg/day, PeptiSleep 500 mg/day |
| Placebo MCC micro-crystalline cellulosePlacebo MCC micro-crystalline cellulose | Dietary supplement | Microcrystalline Cellulose 500mg/day |
Primary outcome
Safety and Tolerability of a dose range of PeptiSleep via adverse event reporting
Time frame: Day 0 to 56
Change from baseline to the end of the study period in safety via adverse event reporting and incident rate ratio between placebo and a dose range of PeptiSleep
19 secondary outcomes
Safety via electrolytes and liver function tests
Time frame: Day 0 to 56
Sleep Quality via Leeds Sleep Evaluation Questionnaire
Time frame: Day 0 to 56
Insomnia severity via the Insomnia Severity Index Questionnaire
Time frame: Day 0 to 56
Sleep onset time via self-reported recording in a Sleep Diary
Time frame: Day 0 to 56
Sleep pattern via self-reported recording in a Sleep Diary
Time frame: Day 0 to 56
Daytime Sleepiness via the Epworth Sleepiness Scale
Time frame: Day 0 to 56
Stress via the Perceived Stress Scale
Time frame: Day 0 to 56
Stress via self reported Profile of Mood States Questionnaire
Time frame: Day 0 to 56
Anxiety via self-reported Beck Anxiety Inventory questionnaire
Time frame: Day 0 to 56
Stress via Salivary cortisol test
Time frame: Day 0 to 56
Alertness via Reaction Time Test
Time frame: Day 0 to 56
Circadian cycles via melatonin and serotonin via blood test
Time frame: Day 0 to 56
Markers associated with inflammation via blood test
Time frame: Day 0 to 56
Sleep onset latency via wearable sleep tracker
Time frame: Day 0 to 56
Total sleep time spent in sleep phases via wearable sleep tracker
Time frame: Day 0 to 56
Blood pressure via blood pressure machine
Time frame: Day 0 to 56
Heart rate via blood pressure machine
Time frame: Day 0 to 56
Body Temperature via wearable sleep tracker
Time frame: Day 0 to 56
BMI via height and weight measurements
Time frame: Day 0 to 56
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Mar 2025.
- Individual participant dataSharing planned: No
Related trials for Sleep
Recruiting
NightWare and Cardiovascular Health in Women With PTSD
Post Traumatic Stress Disorder, Cardiovascular Diseases
Recruiting
Addressing Nocturia in Older Women Utilizing Behavioral Sleep Intervention and Brief Mindfulness
Nocturia, Insomnia
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Recruiting
Investigation of the Effects of Sleep Deprivation on Itch and Pain Sensitivity
Histamine, Cowhage
Not yet recruiting
REM Enhancement Sleep Technology for Well-being, Emotion, and Life Lift
Healthy Adult Participants
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing PeptiSleep in people with Sleep, run by Nuritas Ltd at 1 site in Australia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety and Tolerability of a dose range of PeptiSleep via adverse event reporting (time frame: Day 0 to 56). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Mar 2025.